StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Equities researchers at StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSOGet Free Report) in a report issued on Wednesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright lifted their target price on Ekso Bionics from $9.25 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th.

Check Out Our Latest Analysis on Ekso Bionics

Ekso Bionics Stock Down 1.8 %

NASDAQ EKSO opened at $1.09 on Wednesday. The company has a quick ratio of 2.11, a current ratio of 2.81 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average of $1.27 and a two-hundred day moving average of $1.64. The firm has a market capitalization of $19.81 million, a price-to-earnings ratio of -1.12 and a beta of 1.49. Ekso Bionics has a 52 week low of $0.62 and a 52 week high of $3.13.

Ekso Bionics (NASDAQ:EKSOGet Free Report) last posted its quarterly earnings data on Monday, April 29th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The firm had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $4.99 million. Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. During the same period in the previous year, the firm earned ($0.33) earnings per share. On average, analysts predict that Ekso Bionics will post -0.43 earnings per share for the current year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSOFree Report) by 322.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. 6.42% of the stock is currently owned by institutional investors.

About Ekso Bionics

(Get Free Report)

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.

Featured Stories

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.